{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:40:23Z","timestamp":1790091623125,"version":"4.0.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,11]]},"DOI":"10.1182\/bloodadvances.2024014982","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T18:18:01Z","timestamp":1735323481000},"page":"1159-1162","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report"],"prefix":"10.1182","volume":"9","author":[{"given":"Xiaoyuan","family":"He","sequence":"first","affiliation":[{"name":"1Department of Hematology, Tianjin First Central Hospital, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Nankai University School of Medicine, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Yu","sequence":"additional","affiliation":[{"name":"3Department of Hematology, West China Hospital, Sichuan University, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanxia","family":"Meng","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tianjin First Central Hospital, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tianjin First Central Hospital, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhao","sequence":"additional","affiliation":[{"name":"4Tianjin Medical University, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairong","family":"Lyu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tianjin First Central Hospital, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tianjin First Central Hospital, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tianjin First Central Hospital, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Tianjin First Central Hospital, Tianjin, People's Republic of China"},{"name":"2Nankai University School of Medicine, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"22","key":"2025032513480390800_bib1","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T\u00a0cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2025032513480390800_bib2","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"2025032513480390800_bib3","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, open-label study of ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor-T-cell therapy, in Chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2025032513480390800_bib4","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B\u00a0cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"2025032513480390800_bib5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","article-title":"Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma","volume":"7","author":"Frigault","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2025032513480390800_bib6","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A\u00a0phase I study of anti-BCMA CAR T cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"issue":"18","key":"2025032513480390800_bib7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2025032513480390800_bib8","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3324\/haematol.2022.280629","article-title":"A\u00a0novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed\/refractory multiple myeloma: results from phase I clinical trials","volume":"107","author":"Yang","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2025032513480390800_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13045-023-01461-1","article-title":"Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting","volume":"16","author":"Xia","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2025032513480390800_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","article-title":"Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma","volume":"9","author":"Yu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2025032513480390800_bib11","doi-asserted-by":"crossref","first-page":"e008429","DOI":"10.1136\/jitc-2023-008429","article-title":"PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion","volume":"12","author":"Ouyang","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"2025032513480390800_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2025032513480390800_bib13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ajh.26583","article-title":"CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status","volume":"97","author":"Du","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"2025032513480390800_bib20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ymthe.2023.12.018","article-title":"Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain","volume":"32","author":"Mikkilineni","year":"2024","journal-title":"Mol Ther"},{"issue":"7","key":"2025032513480390800_bib18","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.3324\/haematol.2022.281628","article-title":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed\/refractory multiple myeloma: results from a phase I clinical trial","volume":"108","author":"Asherie","year":"2023","journal-title":"Haematologica"},{"issue":"9","key":"2025032513480390800_bib15","doi-asserted-by":"crossref","first-page":"e005145","DOI":"10.1136\/jitc-2022-005145","article-title":"Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"10","author":"Qu","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"21","key":"2025032513480390800_bib16","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A\u00a0phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"10297","key":"2025032513480390800_bib14","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"19","key":"2025032513480390800_bib17","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2025032513480390800_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A\u00a0phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"13","key":"2025032513480390800_bib22","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025032513480390800_bib23","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"2025032513480390800_bib24","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1200\/JCO.22.01824","article-title":"Anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase \u2161 trial","volume":"41","author":"Xia","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"485","key":"2025032513480390800_bib21","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"suppl 1","key":"2025032513480390800_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1159\/2357737\/blooda_adv-2024-014982-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/5\/1159\/2357737\/blooda_adv-2024-014982-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:06:49Z","timestamp":1742951209000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/5\/1159\/534847\/Anti-FcRL5-CAR-T-exhibits-anti-MM-activity-against"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014982","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}